Genasense

oblimersen sodium

FDA Extends Review of Genasense NDA Appeal in Chronic Lymphocytic Leukemia

BERKELEY HEIGHTS, N.J., January 14, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated announced today that the Food and Drug Administration (FDA) has extended its review of Genta's appeal of the non- approvable decision for a New Drug Application (NDA) that proposed the use of Genasense (oblimersen sodium injection) plus chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia. The Company had previously provided guidance that a final decision would be available in the fourth quarter of 2007. Genta now envisions receiving this notification later in the current quarter.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.

Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

    -- the Company's ability to obtain necessary regulatory approval for

       Genasense from the U.S. Food and Drug Administration ("FDA") or

       European Medicines Agency ("EMEA");

    -- the safety and efficacy of the Company's products or product

       candidates;

    -- the Company's assessment of its clinical trials;

    -- the commencement and completion of clinical trials;

    -- the Company's ability to develop, manufacture, license and sell its

       products or product candidates;

    -- the Company's ability to enter into and successfully execute license

       and collaborative agreements, if any;

    -- the adequacy of the Company's capital resources and cash flow

       projections, and the Company's ability to obtain sufficient financing

       to maintain the Company's planned operations;

    -- the adequacy of the Company's patents and proprietary rights;

    -- the impact of litigation that has been brought against the Company and

       its officers and directors and any proposed settlement of such

       litigation;

    -- the Company's ability to regain compliance with the NASDAQ's listing

       qualifications; and

    -- the other risks described under Certain Risks and Uncertainties Related

       to the Company's Business, as contained in the Company's Annual Report

       on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

    CONTACT:


    Nichol Harber

    Genta Investor Relations

    908-286-3980

    

CONTACT: Nichol Harber, Genta Investor Relations, +1-908-286-3980, info@genta.com

Web site: http://www.genta.com/

Ticker Symbol: (NASDAQ-NMS:GNTA)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Related Articles:

FDA Accepts Genta's NDA Amendment as Complete Response for Genasense Treatment of Chronic Lymphocytic Leukemia - July 14, 2008

Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia - June 6, 2008

FDA Indicates That Genasense Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data - March 17, 2008

Genta Completes Appeal of FDA Decision for Genasense in CLL - October 25, 2007

Genta Appeals FDA Decision on Genasense in CLL - April 4, 2007

Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense in Chronic Lymphocytic Leukemia - February 6, 2007

Genta Receives Non-Approvable Notice for Application of Genasense in Patients With Chronic Lymphocytic Leukemia - December 15, 2006

FDA Extends Review Period for Genasense New Drug Application in Chronic Lymphocytic Leukemia - October 30, 2006

Briefing Documents Posted for FDA Committee Review of Genasense New Drug Application - September 5, 2006

Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense as Treatment for Chronic Lymphocytic Leukemia - July 27, 2006

Genasense New Drug Application Accepted for Review by FDA - March 1, 2006

Genta Files New Drug Application for FDA Approval of Genasense Plus Chemotherapy for Patients with Advanced or Refractory Chronic Lymphocytic Leukemia - December 29, 2005

Genta Initiates New Drug Application for Genasense in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia - June 30, 2005

Genta Announces Withdrawal of New Drug Application for Genasense in Melanoma - May 13, 2004

FDA Advisory Committee Reviews Genasense For Use in Advanced Melanoma - May 3, 2004

Genta and Aventis Announce Genasense Expanded Access Program for Patients with Advanced Melanoma - April 20, 2004

Aventis and Genta Announce FDA Acceptance and Priority Review of New Drug Application for Genasense in Advanced Melanoma - February 6, 2004

Latest New Drug Applications...

Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals